Overview

Join Dr Rohan Bhandari (Washington University, St Louis, US), Dr Jose Alvarez-Cardona (New York University School of Medicine, US) and Dr Dan Lenihan (Saint Francis Healthcare System, US) for this month's Journal Club where faculty will tackle critical research in the developing field of cardio-oncology. 

Learn about the safety and tolerability profiles of Zanubrutinib and Ibrutinib in patients with B-cell malignancies. Our expert panel will compare outcomes from a large safety database, helping you understand critical differences and potential impacts on patient care.

The partnership combines Radcliffe’s rapidly growing global community and expertise in delivering the most innovative virtual events, with the knowledge and experience of IC-OS’s members, to curate broadcasts that challenge current practice and have real-world patient benefits.

This webinar is for cardiologists, haematologists, oncologists, nurse practitioners, nurses and pharmacists.

The International Cardio-Oncology Society is a committed group of professionals throughout the world who are striving to protect the cardiovascular health of all patients who are undergoing cancer therapy. By optimising the cardiac status of patients with cancer before, during and after their treatment, IC-OS is collectively improving the overall outcomes including survival and quality of life. IC-OS aims to provide the latest scientific and clinical education and research for anyone treating patients with cancer in the hopes of enhancing cardiovascular protection.

Support Statement
This is an independent activity run by the International Cardio-oncology Society (ICOS) and co-produced in collaboration with Radcliffe Cardiology. IC-OS has been provided support to deliver this webinar series by AstraZeneca, BeiGene, BMS/Pfizer Alliance, Eli Lilly and Sumitomo Pharma through an unrestricted educational grant to cover organisational costs and has had no input into the agenda or content of this educational activity. Radcliffe Cardiology has received no industry funding.